Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an important role in the disease ...

Inflammatory bowel disease (IBD) is expected to be more accurate and personalized. Recently, Professor Lee Hong-seop's team ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, drugmaker Johnson & Johnson announced on Thursday. An interleukin (IL)-23 ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

When it's severe and regular, it could be that you suffer from inflammatory bowel disease (IBD). And while it’s not totally ...

Studies show how some plant foods can reduce inflammation, prevent flare-ups and even lower surgery risks for those with Crohn's disease and ulcerative colitis.